Intelligence Platform
Patents
Browse 565 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 10548856
Compounds and methods for modulating serotonin receptors in the periphery
granted patentUS 10538570
Targeted and modular exosome loading system
granted patentUS 10525086
Methods for growth and maturation of ovarian follicles
granted patentUS 10517924
High density lipoprotein nanoparticles for inflammation
granted patentUS 10500156
Multi-compartmental macrophage delivery
granted patentUS 10500218
Uptake of pharmaceuticals within cyclodextrin-based porous materials
granted patentUS 10501435
Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activ
granted patentUS 10479980
Artificial ovary
granted patentUS 10466259
Synthetic antigen compositions for detecting anti-phosphatidylethanolamine antibodies
granted patentUS 10463745
Materials for tissue regeneration
granted patentUS 10443049
Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
granted patentUS 10442812
Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for
granted patentUS 10434225
Para-xylene films and therapeutic uses thereof
granted patentUS 10435375
CXCR4 chemokine receptor modulators
granted patentUS 10428047
MAP kinase modulators and uses thereof
granted patentUS 10428200
Immobilization of an active agent on a substrate using compounds including trihydroxypheny
granted patentUS 10413565
Nanostructures for modulating intercellular communication and uses thereof
granted patentUS 10406249
Gd(III)-dithiolane gold nanoparticle conjugates
granted patentUS 10406385
Photoluminescent panthenol citrate biomaterials
granted patentUS 10398784
Nanoconjugates able to cross the blood-brain barrier
granted patentUS 10391112
Cationic polymers as co-drugs for chemotherapeutic agents
granted patentUS 10391116
Polyvalent RNA-nanoparticle compositions
granted patentUS 10376515
Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activati
granted patentUS 10377801
Amelioration of chronic kidney disease
granted